Kimberly Hoang, MD
Neurological Surgery · Houston, TXNPI 1093071029
Payments from drug & device makers
Across 73 payments — averaging $1763.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GT Medical Technologies, Inc$107K
- Verastem, Inc.$19K
- Medtronic$781
- Novocure Inc.$610
- Monteris Medical Corporation$298
- Spineology Inc.$218
- plus $190 from 3 others
Across 2 payments — averaging $6300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NX Development Corp.$13K
What the payments were for
- Consulting fees$2,50039%
- Speaking & faculty fees$75012%
- Travel & lodging$1,15118%
- Food & beverage$1,97031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GT Medical Technologies, Inc | 55 | $107,141 |
| Verastem, Inc. | 2 | $19,469 |
| Medtronic | 6 | $781 |
| Novocure Inc. | 4 | $610 |
| Monteris Medical Corporation | 2 | $298 |
| Spineology Inc. | 1 | $218 |
| Alphatec Spine, Inc | 1 | $140 |
| Stryker | 1 | $38 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GammaTile$4,070
- VISUALASE$570
- Optune$464
- Neuroblate$298
- OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM$218
- Optune Gio$146
- INVICTUS OPEN$140
How this compares
$128,706 in reported general payments places this provider in the 85th percentile of 582 neurological surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 32 | $327 |
| Dexamethasone | 17 | $282 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $111 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Houston
- Daniel CurryHouston$3M
- Homero AnchondoHouston$799K
- Claudio TatsuiHouston$777K
- Arthur DayHouston$746K
- Andrew RoeserHouston$660K
- Peng ChenHouston$550K
- Daniel YoshorHouston$519K
- Paul HolmanHouston$516K
- Nitin TandonHouston$510K
- Nelson MossHouston$501K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.